Niandi Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Niandi Tan has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Yinglian Xiao
Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
12 shared publications - Mengyu Zhang
Department of Gastroenterology and Hepatology, The First Affiliated Hospital Sun Yat‐sen University Guangzhou China
11 shared publications - Qianjun Zhuang
Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
6 shared publications - Songfeng Chen
Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangdong, China
4 shared publications Song Feng Chen
Department of Gastroenterology The First Affiliated Hospital of Sun Yat‐sen University Guangzhou Guangdong Province China
3 shared publications- Xingyu Jia
Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangdong, China
3 shared publications
Latest Publications
- 9 September 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (10) , 3624-3634
POETry Without Motion: When Per-oral Endoscopic Myotomy (POEM) Fails
- 9 September 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (10) , 3624-3634
POETry Without Motion: When Per-oral Endoscopic Myotomy (POEM) Fails
- 12 February 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (5) , 803-813
Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis
INTRODUCTION: Los Angeles grade C/D esophagitis is a severe manifestation of gastroesophageal reflux disease that require active treatment and close follow-up. Potassium competitive acid blockers (P-CAB) are promising alternatives to proton pump inhibitors (PPI). We aimed to compare the efficacy and safety of P-CAB and PPI in healing grade C/D esophagitis to aid clinical decision-making. METHODS: A systematic literature search was performed using PubMed, MEDLINE, and Cochrane Central Register of Controlled Trials. Randomized controlled trials were eligible for inclusion if efficacy of P-CAB and PPI in healing grade C/D esophagitis was reported. Pooled risk ratios and risk difference with 95% credible intervals were used to summarize estimated effect of each comparison. The benefit of treatments was ranked using the surface under the cumulative probability ranking score. RESULTS: Of 5,876 articles identified in the database, 24 studies were eligible. Studies included incorporated 3 P-CAB (vonoprazan, tegoprazan, and keverprazan) and 6 PPI (lansoprazole, esomeprazole, omeprazole, rabeprazole extended-release (ER), pantoprazole, and dexlansoprazole). Based on the failure to achieve mucosal healing, 20 mg of vonoprazan q.d. ranked the first among PPI in initial and maintained healing of grade C/D esophagitis (surface under the cumulative probability ranking score = 0.89 and 0.87, respectively). Vonoprazan had similar risk of incurring adverse events, severe adverse events, and withdrawal to drug when compared with PPI. For those who attempted lower maintenance treatment dose, 10 mg of vonoprazan q.d. was a reasonable choice, considering its moderate efficacy and safety. DISCUSSION: Vonoprazan has considerable efficacy in initial and maintained healing of grade C/D esophagitis compared with PPI, with moderate short-term and long-term safety.
- 12 February 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (5) , 803-813
Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis
INTRODUCTION: Los Angeles grade C/D esophagitis is a severe manifestation of gastroesophageal reflux disease that require active treatment and close follow-up. Potassium competitive acid blockers (P-CAB) are promising alternatives to proton pump inhibitors (PPI). We aimed to compare the efficacy and safety of P-CAB and PPI in healing grade C/D esophagitis to aid clinical decision-making. METHODS: A systematic literature search was performed using PubMed, MEDLINE, and Cochrane Central Register of Controlled Trials. Randomized controlled trials were eligible for inclusion if efficacy of P-CAB and PPI in healing grade C/D esophagitis was reported. Pooled risk ratios and risk difference with 95% credible intervals were used to summarize estimated effect of each comparison. The benefit of treatments was ranked using the surface under the cumulative probability ranking score. RESULTS: Of 5,876 articles identified in the database, 24 studies were eligible. Studies included incorporated 3 P-CAB (vonoprazan, tegoprazan, and keverprazan) and 6 PPI (lansoprazole, esomeprazole, omeprazole, rabeprazole extended-release (ER), pantoprazole, and dexlansoprazole). Based on the failure to achieve mucosal healing, 20 mg of vonoprazan q.d. ranked the first among PPI in initial and maintained healing of grade C/D esophagitis (surface under the cumulative probability ranking score = 0.89 and 0.87, respectively). Vonoprazan had similar risk of incurring adverse events, severe adverse events, and withdrawal to drug when compared with PPI. For those who attempted lower maintenance treatment dose, 10 mg of vonoprazan q.d. was a reasonable choice, considering its moderate efficacy and safety. DISCUSSION: Vonoprazan has considerable efficacy in initial and maintained healing of grade C/D esophagitis compared with PPI, with moderate short-term and long-term safety.
- Open Access
- 30 January 2024
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 30 (1) , 64-72
The Disease Spectrum and Natural History of Patients With Abdominal Bloating or Distension: A Longitudinal Study
Fangfei Chen, Niandi Tan, Songfeng Chen, Qianjun Zhuang, Mengyu Zhang, and Yinglian Xiao. J Neurogastroenterol Motil 2024;30:64-72. https://doi.org/10.5056/jnm22197
- 30 January 2024
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 30 (1) , 64-72
Open AccessThe Disease Spectrum and Natural History of Patients With Abdominal Bloating or Distension: A Longitudinal Study
Fangfei Chen, Niandi Tan, Songfeng Chen, Qianjun Zhuang, Mengyu Zhang, and Yinglian Xiao. J Neurogastroenterol Motil 2024;30:64-72. https://doi.org/10.5056/jnm22197
- 1 January 2024
- Published by Wiley in Journal of Digestive Diseases
- Vol. 25 (1) , 70-74
High‐resolution manometry evaluation and endoscopic myotomy for pediatric cricopharyngeal achalasia: A case report and literature review
- 1 January 2024
- Published by Wiley in Journal of Digestive Diseases
- Vol. 25 (1) , 70-74
High‐resolution manometry evaluation and endoscopic myotomy for pediatric cricopharyngeal achalasia: A case report and literature review
- Open Access
- 3 October 2023
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (1) , e00651
Development and Validation of Serum Markers as Noninvasive Diagnostic Methods for Achalasia
INTRODUCTION: Currently, the diagnosis of achalasia mainly relies on invasive or radioactive examinations. This study aimed to develop a noninvasive diagnostic method for achalasia based on specific serum markers. METHODS: Serum levels of profilin-1, galectin-10, immunoglobulin heavy variable 3–9, vasodilator-stimulated phosphoprotein, and transgelin-2 were measured in patients with achalasia and controls by enzyme-linked immunosorbent assay. The diagnostic values and thresholds were determined by the receiver operating characteristic curve analysis. Then, patients with dysphagia were prospectively enrolled to validate the ability of these molecules for achalasia diagnosing. RESULTS: A total of 142 patients with achalasia and 50 nonachalasia controls (healthy volunteers and patients with reflux esophagitis) were retrospectively included. The serum levels of profilin-1, galectin-10, and transgelin-2 in patients with achalasia were significantly higher than those in healthy volunteers and patients with reflux esophagitis (P all < 0.001). Profilin-1, galectin-10, and transgelin-2 were of good performance in diagnosing achalasia, with optimal thresholds of 2,171.2, 33.9, and 1,630.6 pg/mL, respectively. Second, 40 patients with dysphagia were prospectively enrolled to the validation of achalasia. For profilin-1, the positive predictive value, negative predictive value, sensitivity, and specificity were 100.0%, 64.5%, 45.0%, and 100.0%, respectively. The figures for transgelin-2 were 65.5%, 90.9%, 95.0%, and 50.0%. When both increased, the positive predictive value reached to 100.0%. When both indexes were normal, the negative predictive value was 100.0%. DISCUSSION: Profilin-1 and transgelin-2 were promising biomarkers for achalasia diagnosis and performed better in combination. Further multicenter studies are necessary to verify their application as preliminary screening tools for achalasia.
- 3 October 2023
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (1) , e00651
Open AccessDevelopment and Validation of Serum Markers as Noninvasive Diagnostic Methods for Achalasia
INTRODUCTION: Currently, the diagnosis of achalasia mainly relies on invasive or radioactive examinations. This study aimed to develop a noninvasive diagnostic method for achalasia based on specific serum markers. METHODS: Serum levels of profilin-1, galectin-10, immunoglobulin heavy variable 3–9, vasodilator-stimulated phosphoprotein, and transgelin-2 were measured in patients with achalasia and controls by enzyme-linked immunosorbent assay. The diagnostic values and thresholds were determined by the receiver operating characteristic curve analysis. Then, patients with dysphagia were prospectively enrolled to validate the ability of these molecules for achalasia diagnosing. RESULTS: A total of 142 patients with achalasia and 50 nonachalasia controls (healthy volunteers and patients with reflux esophagitis) were retrospectively included. The serum levels of profilin-1, galectin-10, and transgelin-2 in patients with achalasia were significantly higher than those in healthy volunteers and patients with reflux esophagitis (P all < 0.001). Profilin-1, galectin-10, and transgelin-2 were of good performance in diagnosing achalasia, with optimal thresholds of 2,171.2, 33.9, and 1,630.6 pg/mL, respectively. Second, 40 patients with dysphagia were prospectively enrolled to the validation of achalasia. For profilin-1, the positive predictive value, negative predictive value, sensitivity, and specificity were 100.0%, 64.5%, 45.0%, and 100.0%, respectively. The figures for transgelin-2 were 65.5%, 90.9%, 95.0%, and 50.0%. When both increased, the positive predictive value reached to 100.0%. When both indexes were normal, the negative predictive value was 100.0%. DISCUSSION: Profilin-1 and transgelin-2 were promising biomarkers for achalasia diagnosis and performed better in combination. Further multicenter studies are necessary to verify their application as preliminary screening tools for achalasia.
- Open Access
- 29 May 2023
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 14 (7) , e00602
Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial
INTRODUCTION: Keverprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders requiring potent acid inhibition. This study aimed to establish the noninferiority of keverprazan to lansoprazole in the treatment of patients with duodenal ulcer (DU). METHODS: In this phase III, double-blind, multicenter study, 360 Chinese patients with endoscopically confirmed active DU were randomized 1:1 to take either keverprazan (20 mg) or lansoprazole (30 mg) treatment for up to 6 weeks. The primary end point was DU healing rate at week 6. The secondary end point was DU healing rate at week 4. Symptom improvement and safety were also assessed. RESULTS: Based on the full analysis set, the cumulative healing rates at week 6 were 94.4% (170/180) and 93.3% (166/178) for keverprazan and lansoprazole, respectively (difference: 1.2%; 95% confidence intervel: −4.0%–6.5%). At week 4, the respective healing rates were 83.9% (151/180) and 80.3% (143/178). In the per protocol set, the 6-week healing rates in keverprazan and lansoprazole groups were 98.2% (163/166) and 97.6% (163/167), respectively (difference: 0.6%; 95% confidence intervel: −3.1%–4.4%); the 4-week healing rates were respectively 86.8% (144/166) and 85.6% (143/167). Keverprazan was noninferior to lansoprazole in DU healing after the treatment for 4 and 6 weeks. The incidence of treatment-emergent adverse events was comparable among groups. DISCUSSION: Keverprazan 20 mg had a good safety profile and was noninferior to lansoprazole 30 mg once daily for DU healing.
- 29 May 2023
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 14 (7) , e00602
Open AccessEfficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial
INTRODUCTION: Keverprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders requiring potent acid inhibition. This study aimed to establish the noninferiority of keverprazan to lansoprazole in the treatment of patients with duodenal ulcer (DU). METHODS: In this phase III, double-blind, multicenter study, 360 Chinese patients with endoscopically confirmed active DU were randomized 1:1 to take either keverprazan (20 mg) or lansoprazole (30 mg) treatment for up to 6 weeks. The primary end point was DU healing rate at week 6. The secondary end point was DU healing rate at week 4. Symptom improvement and safety were also assessed. RESULTS: Based on the full analysis set, the cumulative healing rates at week 6 were 94.4% (170/180) and 93.3% (166/178) for keverprazan and lansoprazole, respectively (difference: 1.2%; 95% confidence intervel: −4.0%–6.5%). At week 4, the respective healing rates were 83.9% (151/180) and 80.3% (143/178). In the per protocol set, the 6-week healing rates in keverprazan and lansoprazole groups were 98.2% (163/166) and 97.6% (163/167), respectively (difference: 0.6%; 95% confidence intervel: −3.1%–4.4%); the 4-week healing rates were respectively 86.8% (144/166) and 85.6% (143/167). Keverprazan was noninferior to lansoprazole in DU healing after the treatment for 4 and 6 weeks. The incidence of treatment-emergent adverse events was comparable among groups. DISCUSSION: Keverprazan 20 mg had a good safety profile and was noninferior to lansoprazole 30 mg once daily for DU healing.
- Open Access
- 30 April 2023
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 29 (2) , 145-155
Achalasia: The Current Clinical Dilemma and Possible Pathogenesis
Xingyu Jia, Songfeng Chen, Qianjun Zhuang, Niandi Tan, Mengyu Zhang, Yi Cui, Jinhui Wang, Xiangbin Xing, and Yinglian Xiao*. J Neurogastroenterol Motil 2023;29:145-55. https://doi.org/10.5056/jnm22176
- 30 April 2023
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 29 (2) , 145-155
Open AccessAchalasia: The Current Clinical Dilemma and Possible Pathogenesis
Xingyu Jia, Songfeng Chen, Qianjun Zhuang, Niandi Tan, Mengyu Zhang, Yi Cui, Jinhui Wang, Xiangbin Xing, and Yinglian Xiao*. J Neurogastroenterol Motil 2023;29:145-55. https://doi.org/10.5056/jnm22176
- 19 July 2022
- Published by Wiley in Journal of Digestive Diseases
- Vol. 23 (5-6) , 262-269
Patient‐ and physician‐reported satisfaction with gastroesophageal reflux disease ( GERD ) treatment in Chinese clinical practice
Objective The aim of this study was to assess the level of satisfaction with currently prescribed medications for gastroesophageal reflux disease (GERD) in patients and physicians in China. Methods Physicians across China were invited to complete physician surveys concerning factors affecting the prescription of medication for GERD and their satisfaction through an online questionnaire. The enrolled physicians invited the first five GERD patients who visited them on the same day to complete online patient surveys concerning the satisfaction with medications for GERD and its influencing factors. Results In total, 334 physician surveys (response rate 36.82%) and 1409 patient surveys (86.07%) were analyzed. Over half (62.57%) the physicians recommended taking a proton pump inhibitor (PPI) twice daily and the majority (88.02%) recommended taking a PPI for 1 week to 3 months. Factors affecting the prescription were how much it could improve quality of life (84.73%), followed by safety, medication compliance, and efficacy. Approximately 30% of patients reported taking a PPI twice daily and 47.20% reported taking a PPI for 1 week to 3 months. Factor affecting patients' adherence to medications was safety (64.30%), followed by medical insurance, efficacy and convenience. Approximately one-third of physicians and patients did not report "satisfied" or "very satisfied" with medications for GERD, including 10.51% of patients and 12.87% of physicians reporting "dissatisfied" or "very dissatisfied." Conclusion One-third of GERD patients and physicians were not satisfied or very satisfied with medications for GERD. Novel medications may help optimize the management of GERD.
- 19 July 2022
- Published by Wiley in Journal of Digestive Diseases
- Vol. 23 (5-6) , 262-269
Patient‐ and physician‐reported satisfaction with gastroesophageal reflux disease ( GERD ) treatment in Chinese clinical practice
Objective The aim of this study was to assess the level of satisfaction with currently prescribed medications for gastroesophageal reflux disease (GERD) in patients and physicians in China. Methods Physicians across China were invited to complete physician surveys concerning factors affecting the prescription of medication for GERD and their satisfaction through an online questionnaire. The enrolled physicians invited the first five GERD patients who visited them on the same day to complete online patient surveys concerning the satisfaction with medications for GERD and its influencing factors. Results In total, 334 physician surveys (response rate 36.82%) and 1409 patient surveys (86.07%) were analyzed. Over half (62.57%) the physicians recommended taking a proton pump inhibitor (PPI) twice daily and the majority (88.02%) recommended taking a PPI for 1 week to 3 months. Factors affecting the prescription were how much it could improve quality of life (84.73%), followed by safety, medication compliance, and efficacy. Approximately 30% of patients reported taking a PPI twice daily and 47.20% reported taking a PPI for 1 week to 3 months. Factor affecting patients' adherence to medications was safety (64.30%), followed by medical insurance, efficacy and convenience. Approximately one-third of physicians and patients did not report "satisfied" or "very satisfied" with medications for GERD, including 10.51% of patients and 12.87% of physicians reporting "dissatisfied" or "very dissatisfied." Conclusion One-third of GERD patients and physicians were not satisfied or very satisfied with medications for GERD. Novel medications may help optimize the management of GERD.
- 25 October 2021
- Published by Wiley in Journal of Digestive Diseases
- Vol. 22 (12) , 695-705
Magnetic sphincter augmentation in treating refractory gastroesophageal reflux disease: A systematic review and meta‐analysis
Objective: In this systematic review and meta‐analysis we aimed to determine the efficacy and safety of magnetic sphincter augmentation (MSA) in the management of refractory gastroesophageal reflux disease (rGERD).Methods: Literature search was conducted in PubMed, the Cochrane Library, EMBASE, Web of Science, OpenGrey and ClincalTrials.gov for single‐arm studies evaluating the efficacy and safety of MSA in rGERD or comparative studies with proton pump inhibitor (PPI) or laparoscopic Nissen fundoplication (LNF) serving as the control published until April 2020. Primary outcome was the rate of postoperative PPI use, and secondary outcomes included postoperative GERD‐health‐related quality of life (GERD‐HRQL), normalization of acid exposure time (AET) and incidence of procedure‐related adverse events (AE).Results: Ten single‐arm studies, one randomized controlled trial and three cohort studies involving 1138 participants were included. Post‐MSA PPI withdrawal, significant GERD‐HRQL improvement and AET normalization were achieved in 87.0%, 88.0% and 75.0% of the patients, respectively. The incidence of postoperative dysphagia was 29% and endoscopic dilation was required in 7.4% of patients undergoing MSA. MSA showed a better efficacy in symptom control than PPI (PPI cessation: 91% vs 0%; GERD‐HRQL improvement: 81% vs 8%) and similar effectiveness but a lower risk of gas‐bloat syndrome (risk ratio [RR] 0.69, 95% confidence interval [CI] 0.51‐0.93, P = 0.01) and better reserved ability to belch (RR 1.48, 95% CI 0.76‐2.86, P = 0.25) compared with LNF.Conclusions: MSA was an effective and safe therapy for rGERD. Well‐designed randomized trials that compare the efficacy of MSA with other therapies are needed.
- 25 October 2021
- Published by Wiley in Journal of Digestive Diseases
- Vol. 22 (12) , 695-705
Magnetic sphincter augmentation in treating refractory gastroesophageal reflux disease: A systematic review and meta‐analysis
Objective: In this systematic review and meta‐analysis we aimed to determine the efficacy and safety of magnetic sphincter augmentation (MSA) in the management of refractory gastroesophageal reflux disease (rGERD).Methods: Literature search was conducted in PubMed, the Cochrane Library, EMBASE, Web of Science, OpenGrey and ClincalTrials.gov for single‐arm studies evaluating the efficacy and safety of MSA in rGERD or comparative studies with proton pump inhibitor (PPI) or laparoscopic Nissen fundoplication (LNF) serving as the control published until April 2020. Primary outcome was the rate of postoperative PPI use, and secondary outcomes included postoperative GERD‐health‐related quality of life (GERD‐HRQL), normalization of acid exposure time (AET) and incidence of procedure‐related adverse events (AE).Results: Ten single‐arm studies, one randomized controlled trial and three cohort studies involving 1138 participants were included. Post‐MSA PPI withdrawal, significant GERD‐HRQL improvement and AET normalization were achieved in 87.0%, 88.0% and 75.0% of the patients, respectively. The incidence of postoperative dysphagia was 29% and endoscopic dilation was required in 7.4% of patients undergoing MSA. MSA showed a better efficacy in symptom control than PPI (PPI cessation: 91% vs 0%; GERD‐HRQL improvement: 81% vs 8%) and similar effectiveness but a lower risk of gas‐bloat syndrome (risk ratio [RR] 0.69, 95% confidence interval [CI] 0.51‐0.93, P = 0.01) and better reserved ability to belch (RR 1.48, 95% CI 0.76‐2.86, P = 0.25) compared with LNF.Conclusions: MSA was an effective and safe therapy for rGERD. Well‐designed randomized trials that compare the efficacy of MSA with other therapies are needed.
- 12 August 2021
- Published by Wiley in Journal of Digestive Diseases
- Vol. 22 (9) , 520-528
White‐light endoscopy is insufficient to distinguish between types of esophageal white lesions
Objective: Esophageal white lesions (EWL) are commonly observed under upper endoscopy, while their clinical significance remains undetermined. The aim of this study was to identify the endoscopic characteristics of EWL and distinguish between different types of EWL.Methods: Consecutive patients with upper gastrointestinal complaints and participants admitted for health check‐up who underwent esophagogastroduodenoscopy from October 2018 to August 2019 in a tertiary hospital were prospectively screened. EWL were detected under endoscopy and biopsy was performed for histological analysis. Participants' characteristics, lifestyle, esophageal motility and reflux monitoring variables were analyzed.Results: Of the 3641 consecutive participants screened, 303 of them aged 56.12 ± 10.95 years were found to have EWL (detection rate of 8.3%). More than one‐third of them preferred hot drinks, eating pickled or spicy food, smoking and alcohol consumption and 5.3% had current or former upper gastrointestinal or head and neck cancers. The common endoscopic appearance of the EWL (2.9 mm ± 1.2 mm in diameter) included slightly elevated plaque, translucent white in color, with a clear border, round or oval in shape, and a scaly, rough or smooth surface. Histology showed low‐grade intraepithelial dysplasia in 13 cases, leukoplakia in 10 and intestinal metaplasia in one. No significant differences were found between the histological findings and endoscopic manifestations of EWL.Conclusions: EWL are not uncommon in daily endoscopic examination, with some of them being precancerous lesions. Conventional white‐light endoscopy is insufficient to identify EWL, while histological assessment is important. Further studies using advanced endoscopic techniques with long‐term follow‐up are needed.
- 12 August 2021
- Published by Wiley in Journal of Digestive Diseases
- Vol. 22 (9) , 520-528
White‐light endoscopy is insufficient to distinguish between types of esophageal white lesions
Objective: Esophageal white lesions (EWL) are commonly observed under upper endoscopy, while their clinical significance remains undetermined. The aim of this study was to identify the endoscopic characteristics of EWL and distinguish between different types of EWL.Methods: Consecutive patients with upper gastrointestinal complaints and participants admitted for health check‐up who underwent esophagogastroduodenoscopy from October 2018 to August 2019 in a tertiary hospital were prospectively screened. EWL were detected under endoscopy and biopsy was performed for histological analysis. Participants' characteristics, lifestyle, esophageal motility and reflux monitoring variables were analyzed.Results: Of the 3641 consecutive participants screened, 303 of them aged 56.12 ± 10.95 years were found to have EWL (detection rate of 8.3%). More than one‐third of them preferred hot drinks, eating pickled or spicy food, smoking and alcohol consumption and 5.3% had current or former upper gastrointestinal or head and neck cancers. The common endoscopic appearance of the EWL (2.9 mm ± 1.2 mm in diameter) included slightly elevated plaque, translucent white in color, with a clear border, round or oval in shape, and a scaly, rough or smooth surface. Histology showed low‐grade intraepithelial dysplasia in 13 cases, leukoplakia in 10 and intestinal metaplasia in one. No significant differences were found between the histological findings and endoscopic manifestations of EWL.Conclusions: EWL are not uncommon in daily endoscopic examination, with some of them being precancerous lesions. Conventional white‐light endoscopy is insufficient to identify EWL, while histological assessment is important. Further studies using advanced endoscopic techniques with long‐term follow‐up are needed.